ADC THERAPEUTICS SA (ADCT)
Health Care · Antibody-drug conjugates (ADCs) / targeted oncology therapeutics · NYSE
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
What ADC THERAPEUTICS SA does
ADC Therapeutics is a clinical-stage pharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company commercializes ZYNLONTA (loncastuximab tesirine-lpyl), an ADC for relapsed/refractory diffuse large B-cell lymphoma, while advancing a pipeline of clinical-stage product candidates targeting both hematologic and solid tumors. The company generates revenue from product sales of ZYNLONTA and through license/royalty agreements, though it currently operates at a substantial net loss.
Themes: ["Antibody-drug conjugates (ADCs)"]
Fundamentals
- Price$1.30 as of 2026-07-09 close
- Market cap$165M as of 2026-07-10
- 1-year return-55.4% as of 2026-07-09 close
- Net margin-173.0% as of 2026-07-10
- Gross margin+90.7% as of 2026-07-10
- ROE-229.2% as of 2026-07-10
- Debt / equity9.01 as of 2026-07-10
- Revenue growth (YoY)+4.4% as of 2026-07-10
- Revenue CAGR (3y)-27.1% SEC XBRL
- Beta1.82 as of 2026-07-10
Key risks (from latest filing)
["Substantial accumulated losses and expectation to continue incurring losses; dependence on additional capital raises in uncertain financial markets"]
Competitors & peers
- Seagen (SGEN)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.